<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25387505</article-id>
      <article-id pub-id-type="pmc">4230669</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20143073</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>American tegumentary leishmaniasis - a case of therapeutic challenge<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Couto</surname>
            <given-names>Da&#xED;ne Vargas</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hans Filho</surname>
            <given-names>Gunter</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Medeiros</surname>
            <given-names>Marcelo Zanolli</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vicari</surname>
            <given-names>Carolina Faria Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Aline Blanco</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takita</surname>
            <given-names>Luiz Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> Universidade Federal de Mato Grosso do Sul (UFMS) - Campo Grande (MS),
Brazil.</aff>
      <aff id="aff02"><label>2</label> Hospital S&#xE3;o Juli&#xE3;o - Campo Grande (MS), Brazil.</aff>
      <author-notes>
        <corresp id="c01"><italic>MAILING ADDRESS:</italic> Da&#xED;ne Vargas Couto, Av. Senador
Filinto Muller, 355, Vila Ipiranga, 79080190 - Campo Grande - MS, Brazil. E-mail:
<email>dainevargas@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Nov-Dec</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>6</issue>
      <fpage>974</fpage>
      <lpage>976</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>American Tegumentary Leishmaniasis (ATL) is a chronic, non-contagious, infectious
disease affecting millions of people worldwide. The timely and proper treatment is of
great importance to prevent the disease from progressing to destructive and severe
forms. Treatment for ATL recommended by the Brazilian Ministry of Health is similar
for the whole country, regardless of the species of <italic>Leishmania</italic>. It
is known that the response to treatment may vary with the strain of the parasite, the
immune status of the patient and clinical form. We report the case of a healthy
patient, coming from Manaus, Amazonas state, Brazil, who presented resistance to
treatment with N-methyl-glutamine and liposomal amphotericin B, only being healed
after using pentamidine.</p>
      </abstract>
      <kwd-group>
        <kwd>Leishmania guyanensis</kwd>
        <kwd>Leishmaniasis, cutaneous</kwd>
        <kwd>Pentamidine</kwd>
        <kwd>Skin diseases, parasitic</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>American Tegumentary Leishmaniasis (ATL) is an infectious, chronic, non-contagious
disease that affects millions of people worldwide. It is caused by several species of
protozoa of the <italic>Leishmania</italic> genus and transmitted to men by wild and
domesticated animals through females of Phlebotominae, of which the most common is
<italic>Lutzomya</italic>. The most common species in Brazil are <italic>L.</italic>
(<italic>Viannia</italic>) <italic>braziliensis</italic>, <italic>Leishmania</italic>
(<italic>Viannia</italic>) <italic>guyanensis,</italic> and <italic>L.</italic>
(<italic>Leishmania</italic>) <italic>amazonensis</italic>.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup>
<italic>L. (V.) guyanensis</italic> is the second most prevalent species in Brazil, one
of the most common in the Amazon region. In a study performed in the state of Amazonas,
it was verified that in 88.1% of the patients with ATL the species found was <italic>L.
guyanensis</italic>.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>ATL is currently distributed in all of the states, with the Center-West region now
occupying the third place in prevalence in the national territory.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>It is in a phase of geographical expansion. Analyses of epidemiological studies of ATL
have suggested changes in the behavior of the disease.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Over the years, it was seen as an occupational disease,
affecting adult men exposed to forest regions, but today there is increasing involvement
of women and children, as a consequence of the urbanization process.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>The incubation period of the cutaneous form may vary from one week to one month, whereas
mucosal lesions usually appear from one to two years after the onset of infection. ATL
may present diverse clinical forms, from self-limiting cutaneous lesions to
mucocutaneous disfiguring lesion forms, depending on the immune status of the patient
and species of <italic>Leishmania</italic>. <sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>ATL diagnosis encompasses epidemiological, clinical and laboratorial aspects. The
association of some of these elements is frequently necessary to achieve the final
diagnosis.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Diagnosis is reached
through direct research, culture in specific medium or histopathological test.
Immunological tests, such as Montenegro's intradermal reaction and indirect
immunofluorescence, are indirect methods used.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>Timely and adequate treatment is of great importance to prevent the evolution of the
disease to destructive and severe forms, such as the mucosal form.<sup><xref rid="r04" ref-type="bibr">4</xref></sup> Drugs currently employed present high
toxicity and frequent adverse effects and none of them is sufficiently effective.
<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> Relapse, therapeutical failure in immunodepressed patients and
treatment resistance are factors that motivate the search for an ideal drug.<sup><xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>The drug of choice is N-methylglucamine antimoniate (NMG). As a second-choice treatment
there is pentamidine isethionate and amphotericin B. Other drugs already used for the
treatment of ATL are miltefosine, azithromycin, itraconazole, ketoconazole, allopurinol,
paromomycin and pentoxifylline.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>Although the ATL treatment recommended by the Health Department (Minist&#xE9;rio da Sa&#xFA;de -
MS) is the same for the whole country, regardless of which <italic>Leishmania</italic>
species caused the disease, there are few clinical trials showing the true efficacy of
these drugs. It is known that the response to the treatment with antimony may vary
according to parasite strain, immune status of the patient and clinical form.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup></p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Female patient, 6 years old, originally from Manaus-AM, had resided in Campo Grande-MS
for the last 4 months. Two months ago she progressively developed an erythematous,
crusted and erosive plaque with infiltrated edges, measuring 2.5 cm in diameter in the
distal extensor region of left arm (<xref ref-type="fig" rid="f01">Figure 1</xref>).
Direct investigation (<italic>imprint</italic>) detected amastigote structures
compatible with <italic>Leishmania sp</italic>. Histopathological examination revealed
epidermis with pseudoepitheliomatous hyperplasia, dermis with a dense inflammatory
infiltrate constituted of lymphocytes, plasmocytes, macrophages and some multinucleated
giant cells. Macrophages containing corpuscles with characteristics of amastigote forms
of <italic>Leishmania</italic> (<xref ref-type="fig" rid="f02">Figure 2</xref>) were
observed. She received N-methylglucamine (NMG) (5.3ml/day for 20 days) with discreet
lesion regression. As she showed no improvement 2 months after the end of the NMG
treatment, liposomal amphotericin B was initiated (total dose of 575mg). Thirty days
after the treatment active lesions still persisted. Suspecting that the
<italic>Leishmania</italic> was acquired in the Amazon region, we began using
pentamidine, prescribing 7mg/kg IM in a single dose. The patient presented regression of
the lesion and a cicatricial plaque remained (<xref ref-type="fig" rid="f03">Figure
3</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Erythematous, erosive and crusted plaque of infiltrated borders, with a 2.5cm
diameter in the distal extensor region of left arm</p>
        </caption>
        <graphic xlink:href="abd-89-06-0974-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Epidermis with pseudoepitheliomatous hyperplasia, dermis with dense inflammatory
infiltrate constituted of lymphocytes, plasmocytes, macrophages and some giant
multinucleated cells. Macrophages were observed containing corpuscles with
characteristics suggesting amastigote forms of Leishmania sp (arrows)</p>
        </caption>
        <graphic xlink:href="abd-89-06-0974-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Atrophic cicatricial plaque after treatment with pentamidine</p>
        </caption>
        <graphic xlink:href="abd-89-06-0974-g03"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In Brazil, patients with cutaneous ATL infected with <italic>L.(V.) b. or L.(V.)
g.</italic> treated with NMG IV or IM during 20 days have had healing rates of 50.8%
e 26.3% respectively. The conclusion was that the leishmania species constitutes a
predictor in the treatment success with NMG.<sup><xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>According to some studies, in the treatment of ATL by <italic>L. (V.)
guyanensis</italic>, pentamidine would be the drug of choice in the state of
Amazonas. Pentamidine would be an important therapeutic option for cutaneous ATL, due to
its cost/benefit, besides being safe for treating cardiopaths.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>Pentamidine is a second-choice drug for the treatment of ATL that does not respond to
pentavalent antimonials, or when their use is contraindicated. The papers of Pradinaud
and Talhari demonstrated good results with low doses of cutaneous ATL caused by
<italic>L. (V.) guyanensis</italic> - total doses close to 1.0g.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>Pentamidine is the first-line drug in Suriname and in French Guiana, where <italic>L.
guyanensis</italic> predominates. In French Guiana, a cure rate of almost 100%, and
in Suriname, of approximately 90% were observed.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>Few studies were performed in the Americas using pentamidine as a therapeutic option for
ATL. The classic recommended dose is 4mg/kg/day, through deep intramuscular application,
every 2 days, not exceeding the recommended total dose of 2g.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>The main adverse reactions related to pentamidine are pain, induration and sterile
abscesses at the injection site, nausea, vomiting, dizziness, adynamia, myalgia,
headache, hypotension, syncope, transient hypoglycemia and hyperglycemia. <sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>ATL is a neglected disease. In general, it involves populations with a low socioeconomic
level, has weak political force and is little attractive for the pharmaceutical
industry. One of the great challenges is to increase investments for the search of drugs
with better efficacy, safety, low cost, ease of management and sustainability.
<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>We report a case of cutaneous ATL which presented treatment resistance to NMG and
liposomal amphotericin B. In spite of being in a high prevalence area of ATL, we
interpreted it as acquired in the city of origin (Manaus) and opted for treating it with
pentamidine, for some studies demonstrate that, when treating ATL by <italic>L. (V.)
guyanensis</italic>, pentamidine is the first-line drug in the state of Amazonas.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Couto DV, Hans-Filho G, Medeiros MZ, Vicari CFS, Barbosa
AB, Takita LC. American tegumentary leishmaniasis - a case of therapeutic challenge.
An Bras Dermatol. 2014;89(6):974-6.</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Work performed at the Department of Dermatology, Teaching Hospital, Universidade
Federal do Mato Grosso do Sul (UFMS) - Campo Grande (MS), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murback</surname>
              <given-names>NDN</given-names>
            </name>
            <name>
              <surname>Hans-Filho</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>RAF</given-names>
            </name>
            <name>
              <surname>Nakazato</surname>
              <given-names>KRO</given-names>
            </name>
            <name>
              <surname>Dorval</surname>
              <given-names>MEMC</given-names>
            </name>
          </person-group>
          <article-title>American cutaneous leishmaniasis: clinical, epidemiological and
laboratory studies conducted at a university teaching hospital in Campo Grande,
Mato Grosso do Sul, Brazil</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>55</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">21437523</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guedes</surname>
              <given-names>ACM</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>MLR</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
          <article-title>American tegumentary leishmaniasis: an unusual
presentation</article-title>
          <source>An Bras Dermatol</source>
          <year>2008</year>
          <volume>83</volume>
          <fpage>445</fpage>
          <lpage>449</lpage>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ourives-Neves</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chrusciak-Talhari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>EPN</given-names>
            </name>
            <name>
              <surname>da Silva J&#xFA;nior</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Guerra</surname>
              <given-names>JAO</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>LCL</given-names>
            </name>
            <name>
              <surname>Talhari</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A randomized clinical trial comparing meglumine antimoniate,
pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by
Leishmania guyanensis</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>1092</fpage>
          <lpage>1101</lpage>
          <pub-id pub-id-type="pmid">22281895</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Penna</surname>
              <given-names>GO</given-names>
            </name>
            <name>
              <surname>Domingues</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Siqueira</surname>
              <given-names>JB</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Elkhoury</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Cechinel</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Grossi</surname>
              <given-names>MA</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Dermatological diseases of compulsory notification in
Brazil</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>865</fpage>
          <lpage>877</lpage>
          <pub-id pub-id-type="pmid">22147024</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Da-Silva</surname>
              <given-names>LMR</given-names>
            </name>
            <name>
              <surname>Cunha</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Urbanization of American Cutaneous Leishmaniasis in Campinas - Sao
Paulo (SP) and region: problems and challenges</article-title>
          <source>An Bras Dermatol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>515</fpage>
          <lpage>519</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lima</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Porto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Motta</surname>
              <given-names>JCO</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>RNR</given-names>
            </name>
          </person-group>
          <article-title>Treatment of American cutaneous leishmaniasis</article-title>
          <source>An Bras Dermatol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>111</fpage>
          <lpage>124</lpage>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sampaio</surname>
              <given-names>RNR</given-names>
            </name>
            <name>
              <surname>Lucas</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Costa Filho</surname>
              <given-names>AV</given-names>
            </name>
          </person-group>
          <article-title>The use of azythromycin and N-methyl glucamine for the treatment of
cutaneous Leishmaniasis caused by Leishmania (Leishmania) amazonensis in C57BL6
mice</article-title>
          <source>An Bras Dermatol</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>125</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="pmid">19503979</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lima</surname>
              <given-names>MVN</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>RZ</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Cerino</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Silveira</surname>
              <given-names>TGV</given-names>
            </name>
          </person-group>
          <article-title>American cutaneous leishmaniasis with fatal outcome during pentavalent
antimoniate treatment</article-title>
          <source>An Bras Dermatol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>269</fpage>
          <lpage>271</lpage>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Brasil</collab>
            <collab>Minist&#xE9;rio da Sa&#xFA;de</collab>
            <collab>Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de</collab>
          </person-group>
          <source>Manual de Vigil&#xE2;ncia da Leishmaniose Tegumentar Americana</source>
          <edition>2. ed. atual</edition>
          <publisher-loc>Bras&#xED;lia</publisher-loc>
          <publisher-name>Editora do Minist&#xE9;rio da Sa&#xFA;de</publisher-name>
          <year>2010</year>
          <size units="pages">180 p</size>
          <comment>(S&#xE9;rie A. Normas e Manuais T&#xE9;cnicos)</comment>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lai A Fat</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Vrede</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Soetosenojo</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lai A Fat</surname>
              <given-names>RF</given-names>
            </name>
          </person-group>
          <article-title>Pentamidine, the drug of choice for the treatment of cutaneous
leishmaniasis in Surinam</article-title>
          <source>Int J Dermatol</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>796</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="pmid">12453009</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
